Data regarding overdose of hyaluronidase is not readily available.L13338 In the even of an overdose, treat patients with symptomatic and supportive measures.
A purified preparation of the enzyme recombinant human hyaluronidase. Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20).A4033 Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.L13338 The action of hyaluronidase was first described in 1936, and named in 1939.A199026 Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue.A199026 Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.A199047
Hyaluronidase was first used in prescription products in the United States on 5 May 2004.L13338
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Dopamine | The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Dopamine. |
| Betamethasone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Betamethasone. |
| Fluocinolone acetonide | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluocinolone acetonide. |
| Triamcinolone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Triamcinolone. |
| Hydrocortisone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Hydrocortisone. |
| Methylprednisolone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methylprednisolone. |
| Trilostane | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Trilostane. |
| Dexamethasone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Dexamethasone. |
| Corticotropin | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Corticotropin. |
| Cortisone acetate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cortisone acetate. |
| Paramethasone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Paramethasone. |
| Aldosterone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Aldosterone. |
| Fluprednidene | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluprednidene. |
| Fluprednisolone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluprednisolone. |
| Meprednisone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Meprednisone. |
| Dexamethasone isonicotinate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Dexamethasone isonicotinate. |
| Melengestrol | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Melengestrol. |
| Cortivazol | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cortivazol. |
| Prednylidene | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Prednylidene. |
| Fluocortin | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluocortin. |
| Fluperolone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluperolone. |
| Fluclorolone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluclorolone. |
| Hydrocortisone succinate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Hydrocortisone succinate. |
| Prednisolone hemisuccinate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Prednisolone hemisuccinate. |
| Methylprednisolone hemisuccinate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methylprednisolone hemisuccinate. |
| Prednisone acetate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Prednisone acetate. |
| Clocortolone acetate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Clocortolone acetate. |
| Melengestrol acetate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Melengestrol acetate. |
| Betamethasone phosphate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Betamethasone phosphate. |
| Prednisolone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Prednisolone. |
| Clobetasol propionate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Clobetasol propionate. |
| Prednisolone acetate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Prednisolone acetate. |
| Fluorometholone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluorometholone. |
| Cloprednol | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cloprednol. |
| Salicylic acid | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Salicylic acid. |
| Dersalazine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Dersalazine. |
| Phenyl aminosalicylate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Phenyl aminosalicylate. |
| Nitroaspirin | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Nitroaspirin. |
| Aloxiprin | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Aloxiprin. |
| Guacetisal | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Guacetisal. |
| Thiosalicylic acid | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Thiosalicylic acid. |
| Acetylsalicylic acid | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Acetylsalicylic acid. |
| Lidocaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Bupivacaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Bupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Cinchocaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Dyclonine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Dyclonine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Prilocaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Prilocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Proparacaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Oxybuprocaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Mepivacaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Mepivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Benzocaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Tetrodotoxin | Hyaluronidase (human recombinant) can cause an increase in the absorption of Tetrodotoxin resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Benzyl alcohol | Hyaluronidase (human recombinant) can cause an increase in the absorption of Benzyl alcohol resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Etidocaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Articaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Tetracaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Butamben | Hyaluronidase (human recombinant) can cause an increase in the absorption of Butamben resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Butacaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Butacaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Butanilicaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Butanilicaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Metabutethamine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Metabutethamine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Quinisocaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Quinisocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Propoxycaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Propoxycaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Procaine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Phenol | Hyaluronidase (human recombinant) can cause an increase in the absorption of Phenol resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Benzatropine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Benzatropine. |
| Ziprasidone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Ziprasidone. |
| Olanzapine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Olanzapine. |
| Cetirizine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cetirizine. |
| Promazine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Promazine. |
| Imipramine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Imipramine. |
| Chlorpromazine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Chlorpromazine. |
| Cimetidine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cimetidine. |
| Hydroxyzine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Hydroxyzine. |
| Risperidone | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Risperidone. |
| Benzquinamide | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Benzquinamide. |
| Propiomazine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Propiomazine. |
| Brompheniramine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Brompheniramine. |
| Ranitidine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Ranitidine. |
| Methdilazine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methdilazine. |
| Famotidine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Famotidine. |
| Methantheline | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methantheline. |
| Azelastine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Azelastine. |
| Dimenhydrinate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Dimenhydrinate. |
| Promethazine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Promethazine. |
| Diphenhydramine | Hyaluronidase (human recombinant) can cause an increase in the absorption of Diphenhydramine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Chlorpheniramine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Chlorpheniramine. |
| Orphenadrine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Orphenadrine. |
| Cyclizine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cyclizine. |
| Aripiprazole | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Aripiprazole. |
| Methotrimeprazine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methotrimeprazine. |
| Aceprometazine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Aceprometazine. |
| Phenindamine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Phenindamine. |
| Zuclopenthixol | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Zuclopenthixol. |
| Methapyrilene | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methapyrilene. |
| Esmirtazapine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Esmirtazapine. |
| Chloropyramine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Chloropyramine. |
| Metiamide | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Metiamide. |
| Roxatidine acetate | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Roxatidine acetate. |
| Dimetotiazine | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Dimetotiazine. |
| Butriptyline | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Butriptyline. |